Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q4, 2016 By the Numbers : June 24, 2016

Posted by CapitalCube on June 24, 2016 in Yahoo Finance | Views | Leave a response

Click here to see latest analysis

Elite Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2016.
We analyze the earnings along side the following peers of Elite Pharmaceuticals, Inc. – Mylan N.V., Acura Pharmaceuticals, Inc., Cambrex Corporation, Aceto Corporation, Nektar Therapeutics, Pfizer Inc., Akorn, Inc. and Albany Molecular Research, Inc. (MYL-US, ACUR-US, CBM-US, ACET-US, NKTR-US, PFE-US, AKRX-US and AMRI-US) that have also reported for this period.

Highlights

• Summary numbers: Revenues of USD 5.19 million, Net Earnings of USD 22.64 million.

• Gross margins widened from 26.78% to 76.71% compared to the same period last year, operating (EBITDA) margins now 14.30% from -447.54%.

• Year-on-year change in operating cash flow of 115.72% is about the same as the change in earnings, likely no significant movement in accruals or reserves.

• Earnings growth from operating margin improvements as well as one-time items.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31
Relevant Numbers (Quarterly)
Revenues (mil)	1.23	2.16	2.7	2.19	5.19
Revenue Growth (%YOY)	20.12	86.2	114.62	60.97	320.89
Earnings (mil)	-9.07	11.16	-7	-37.02	22.64
Earnings Growth (%YOY)	89.56	353.55	-132.75	-276.14	349.77
Net Margin (%)	-734.47	515.97	-259.7	-1687.37	435.85
EPS	-0.01	0.01	-0.01	-0.05	0.03
Return on Equity (%)	N/A	N/A	-269.01	-2841.03	1991.74
Return on Assets (%)	-140.49	159.92	-95.58	-530.45	306.96

Access our Ratings and Scores for Elite Pharmaceuticals, Inc.